المؤلفون: A. Yakovlev V., S. Shilov N., E. Berezikova N., N. Yakovleva F., A. Teplyakov T., E. Grakova V., K. Kopeva V., I. Efremov A., А. Яковлев В., С. Шилов Н., Е. Березикова Н., Н. Яковлева Ф., А. Тепляков Т., Е. Гракова В., К. Копьева В., И. Ефремов А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 17, No 3 (2021); 444-449 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 3 (2021); 444-449 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: heart failure, arterial hypertension, obstructive sleep apnea, valsartan/sacubitril, CPAP therapy, сердечная недостаточность, артериальная гипертензия, обструктивное апноэ сна, валсартан/сакубитрил, СИПАП-терапия

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2502/2183; van Deursen VM, Urso R, Laroche C, et al. Comorbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail. 2014;16:103-11. DOI:10.1002/ejhf.30.; Lindberg E, Gislason T. Epidemiology of sleep-related obstructive breathing. Sleep Med Rev. 2000;4:321-7. DOI:10.1053/smrv.2000.0118.; Mentz RJ, Fiuzat M. Sleep-Disordered Breathing in Patients with Heart Failure Heart Failure Clin. 2014;10:243-50. DOI:10.1016/j.hfc.2013.10.001.; Butt M, Dwivedi G, Khair O, et al. Obstructive sleep apnea and cardiovascular disease. Int J Cardiol. 2010;139:7-16. DOI:10.1016/j.ijcard.2009.05.021.; Marin JM, Agusti A, Villar I, et al. Association Between Treated and Untreated Obstructive Sleep Apnea and Risk of Hypertension. JAMA. 2012;307(20):2169-76. DOI:10.1001/jama.2012.3418.; Bitter T, Westerheide N, Prinz C, et al. Cheyne-Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. Eur Heart J. 2011;32:61-74. DOI:10.1093/eurheartj/ehq327.; Nieto FJ, Young TB, Lind BК, et al. Association of sleep-disordered breathing, sleep apnea and hypertension in a large community-based study. JAMA. 2000;283(14):1829-36. DOI:10.1001/jama.283.14.1829.; Sauer AJ, Cole R, Jensen BC, et al. Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev. 2019;24(2):167-76. DOI:10.1007/s10741-018-9757-1.; Khder Y, Shi V, McMurray JJV, et al. Sacubitril/Valsartan (LCZ696) in Heart Failure. Handb Exp Pharmacol. 2017;243:133-65. DOI:10.1007/164_2016_77.; Denker MG, Cohen DL. Use of continuous positive airway pressure for sleep apnea in the treatment of hypertension. Curr Opin Nephrol Hypertens. 2014;23(5):462-67. DOI:10.1097/MNH.0000000000000047.; Mansukhani MP, Vungarala S, Somers VK. Cardiovascular Benefits of Continuous Positive Airway Pressure: The Quest Continues. Ann Am Thorac Soc. 2020;17(4):427-28. DOI:10.1513AnnalsATS.202001-026ED.; Carmo J, Araújo I, Marques F, et al. Sleep-disordered breathing in heart failure: The state of the art after the SERVE-HF trial. Rev Port Cardiol. 2017;36(11):859-67. DOI:10.1016/j.repc.2017.06.007.; Мареев В.Ю., Фомин И.В., Агеев Ф.Т., и др. Клинические рекомендации ОССНРКО-РНМОТ. сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158. DOI:10.18087/cardio.2475.; Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):479-504. DOI:10.5664/jcsm.6506.; ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-7. DOI:10.1164/ajrccm.166.1.at1102.; Javaheri S, Caref EB, Chen E, et al. Sleep apnea testing and outcomes in a large cohort of medicare beneficiaries with newly diagnosed heart failure. Am J Respir Crit Care Med. 2011;183:539-46. DOI:10.1164/rccm.201003-0406OC.; Liu Y, Huang Z, Huang K, et al. The Clinical Value of N-Terminal Pro B-Type Natriuretic Peptide in Evaluating Obstructive Sleep Apnea in Patients With Coronary Artery Disease. J Clin Sleep Med. 2019;15(10):1403-9. DOI:10.5664/jcsm.7962.; Hübner RH, Mokhtari NE, Freitag S, et al. NT-proBNP is not elevated in patients with obstructive sleep apnoea. Respir Med. 2008;102(1):134-42. DOI:10.1016/j.rmed.2007.07.023.; Kasai T, Bradley TD. Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications. J Am Coll Cardiol. 2011;57(2):119-27. DOI:10.1016/j.jacc.2010.08.627.; Tugcu A, Guzel D, Yildirimturk O, et al. Evaluation of right ventricular systolic and diastolic function in patients with newly diagnosed obstructive sleep apnea syndrome without hypertension. Cardiology. 2009;113:184-92. DOI:10.1159/000193146.; Tasci S, Manka R, Scholtyssek S, et al. NT-pro-BNP in obstructive sleep apnea syndrome is decreased by nasal continuous positive airway pressure. Clin Res Cardiol. 2006;95(1):23-30. DOI:10.1007/s00392-006-0315-9.; Nakamura S, Asai K, Kubota Y, et al. Impact of sleep-disordered breathing and efficacy of positive airway pressure on mortality in patients with chronic heart failure and sleepdisordered breathing: a meta-analysis. Clin Res Cardiol. 2015;104:208-16. DOI:10.1007/s00392-014-0774-3.; Arias MA, García-Río F, Alonso-Fernández A, et al. Pulmonary hypertension in obstructive sleep apnoea: Effects of continuous positive airway pressure: A randomized, controlled cross-over study. Eur Heart J. 2006;27:1106-13. DOI:10.1093/eurheartj/ehi807.; https://www.rpcardio.com/jour/article/view/2502

الاتاحة: https://www.rpcardio.com/jour/article/view/2502
https://doi.org/10.20996/1819-6446-2021-06-07